CDK4 is altered in 66.07% of liposarcoma patients with CDK4 Amplification present in 68.45% of all liposarcoma patients [4].

CDK4 Amplification is an inclusion criterion in 2 clinical trials for liposarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [5].

Palbociclib has evidence of efficacy in patients with CDK4 Amplification in liposarcoma [5].

CDK4 is altered in 2.46% of malignant solid tumor patients with CDK4 Amplification present in 2.08% of all malignant solid tumor patients [4].

CDK4 Amplification is an inclusion criterion in 7 clinical trials for malignant solid tumor, of which 7 are open and 0 are closed. Of the trials that contain CDK4 Amplification and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [5].

CDK4 is altered in 9.22% of malignant glioma patients with CDK4 Amplification present in 10.97% of all malignant glioma patients [4].

CDK4 Amplification is an inclusion criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain CDK4 Amplification and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) [5].

CDK4 is altered in 1.21% of breast carcinoma patients with CDK4 Amplification present in 0.74% of all breast carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDK4 Amplification and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [5].

CDK4 is altered in 3.49% of non-small cell lung carcinoma patients with CDK4 Amplification present in 3.27% of all non-small cell lung carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK4 is altered in 3.68% of melanoma patients with CDK4 Amplification present in 2.53% of all melanoma patients [4].

CDK4 Amplification is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and melanoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK4 is altered in 2.41% of soft tissue sarcoma patients with CDK4 Amplification present in 2.42% of all soft tissue sarcoma patients [4].

CDK4 Amplification is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK4 is altered in 0.52% of ovarian carcinoma patients with CDK4 Amplification present in 0.36% of all ovarian carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and ovarian carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK4 is altered in 0.71% of colorectal carcinoma patients with CDK4 Amplification present in 0.05% of all colorectal carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

CDK4 is altered in 14.84% of acral lentiginous melanoma patients with CDK4 Amplification present in 16.24% of all acral lentiginous melanoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for acral lentiginous melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and acral lentiginous melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 10.39% of glioblastoma patients with CDK4 Amplification present in 12.34% of all glioblastoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

CDK4 is altered in 8.27% of osteosarcoma patients with CDK4 Amplification present in 8.73% of all osteosarcoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 4.55% of primary peritoneal carcinoma patients with CDK4 Amplification present in 5.0% of all primary peritoneal carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 4.08% of gallbladder carcinoma patients with CDK4 Amplification present in 4.29% of all gallbladder carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 3.86% of lung adenocarcinoma patients with CDK4 Amplification present in 3.7% of all lung adenocarcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK4 is altered in 3.4% of lung carcinoma patients with CDK4 Amplification present in 3.13% of all lung carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 3.45% of chondrosarcoma patients with CDK4 Amplification present in 2.73% of all chondrosarcoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 2.56% of adenocarcinoma of the gastroesophageal junction patients with CDK4 Amplification present in 2.68% of all adenocarcinoma of the gastroesophageal junction patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 1.89% of fallopian tube carcinoma patients with CDK4 Amplification present in 2.27% of all fallopian tube carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 2.55% of leiomyosarcoma patients with CDK4 Amplification present in 1.98% of all leiomyosarcoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and leiomyosarcoma as inclusion criteria, 1 is phase 3 (1 open) [5].

CDK4 is altered in 2.3% of cancer patients with CDK4 Amplification present in 1.95% of all cancer patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains CDK4 Amplification and cancer as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK4 is altered in 1.41% of gastric adenocarcinoma patients with CDK4 Amplification present in 1.21% of all gastric adenocarcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 1.6% of squamous cell lung carcinoma patients with CDK4 Amplification present in 0.88% of all squamous cell lung carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [5].

CDK4 is altered in 0.86% of pancreatic carcinoma patients with CDK4 Amplification present in 0.72% of all pancreatic carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 1.2% of bladder carcinoma patients with CDK4 Amplification present in 0.67% of all bladder carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 1.59% of malignant uterine neoplasm patients with CDK4 Amplification present in 0.64% of all malignant uterine neoplasm patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 1.03% of head and neck carcinoma patients with CDK4 Amplification present in 0.51% of all head and neck carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 0.67% of bile duct carcinoma patients with CDK4 Amplification present in 0.36% of all bile duct carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 0.52% of ovarian epithelial tumor patients with CDK4 Amplification present in 0.35% of all ovarian epithelial tumor patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 0.5% of cervical carcinoma patients with CDK4 Amplification present in 0.3% of all cervical carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 0.5% of prostate carcinoma patients with CDK4 Amplification present in 0.29% of all prostate carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and chordoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 1.99% of endometrial endometrioid adenocarcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 is altered in 0.75% of head and neck squamous cell carcinoma patients [4].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK4 Amplification is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 Amplification and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [5].